1 citations
,
October 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This case report describes a patient developing hidradenitis suppurativa-like lesions after undergoing gamma secretase complex inhibitor therapy for desmoid tumours, illustrating potential skin toxicity linked to the treatment.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reports that 71% of patients treated with the gamma-secretase inhibitor PF-03084014 for desmoid tumors experienced dermatologic side effects, such as follicular lesions and pruritic eruptions, which were managed with topical or systemic treatments.
4 citations
,
December 2024 in “JAAD Case Reports” This review discusses previously reported cases of drug-associated hidradenitis suppurativa linked to various immunomodulating medications but reports no new clinical results.
4 citations
,
February 2016 in “Clinical Pharmacology & Therapeutics” Hair follicle samples effectively show how well the drug MK-0752 targets and engages with the Notch pathway.
This research suggests that plucked hair follicles may serve as a reliable surrogate tissue for tumor biopsies in drug development, based on a mouse model linking hair and tumor pharmacodynamic responses.